Insider Selling: uniQure (NASDAQ:QURE) Director Sells $53,930.58 in Stock

uniQure N.V. (NASDAQ:QURE) Director David Meek sold 1,993 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $53,930.58. Following the sale, the director directly owned 39,747 shares in the company, valued at approximately $1,075,553.82. The trade was a 4.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

uniQure Price Performance

Shares of QURE opened at $27.57 on Monday. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The firm’s 50 day moving average price is $22.52 and its 200 day moving average price is $21.76. The company has a market cap of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. On average, research analysts forecast that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Analyst Ratings Changes

A number of equities research analysts have commented on QURE shares. The Goldman Sachs Group increased their price objective on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, April 20th. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a research report on Tuesday, May 5th. Finally, Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in shares of uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after buying an additional 152,417 shares during the last quarter. Aberdeen Group plc grew its position in shares of uniQure by 6.9% in the 3rd quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock valued at $171,593,000 after buying an additional 189,029 shares during the last quarter. Quinn Opportunity Partners LLC purchased a new position in shares of uniQure in the 3rd quarter valued at $6,281,000. Farallon Capital Management LLC grew its position in shares of uniQure by 3,935.7% in the 3rd quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after buying an additional 551,000 shares during the last quarter. Finally, Boone Capital Management LLC purchased a new position in shares of uniQure in the 3rd quarter valued at $8,599,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.